secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0000950170-24-135766
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma appoints Eric Benevich to board; amends director compensation policy
--------------------------------------------------------------------------------

- Eric Benevich appointed as Class II director effective Dec 10, 2024, term through 2026 annual meeting.
- Granted option to purchase 100,000 shares at Dec 10 closing price, vesting equally over 36 months.
- Amended Non-Employee Director Compensation Policy: annual retainer $40,000; committee fees $5,000–$20,000.
- Initial equity grant for new non-employee directors set at 100,000 options; annual grant 50,000 options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024135766/0000950170-24-135766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024135766/atyr-20241210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-135766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer